Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valero Energy Corporation (VLO), BP plc (ADR) (BP), Codexis, Inc. (CDXS): Why Big Oil Is Ditching Biotechnology

Page 1 of 2

Landing partners with deep pockets will be critical for many developmental stage biotechnology companies looking to take their disruptive platforms to the next level. We’re not talking measly partnerships here (although those are important too). We’re talking major investments. Unfortunately, the prospects for megadeals have taken a hit over the last year. Several well-established energy companies have dropped or distanced themselves from the list of financiers for budding industrial biotechnology companies.

Valero Energy Corporation (NYSE:VLO)

Big oil isn’t abandoning renewable technologies altogether, but many companies have pivoted their focus away from genome hacking and toward more familiar industrial technology. While funding hasn’t necessarily dried up, the nascent industrial biotechnology industry could sure use a little more confidence from global energy leaders. With all of the potential behind bio-based chemicals investors may be left wondering: “What gives?”

Brute force vs. finesse
The oil and chemical industries are dominated by thermocatalytic processes, or those that use high heat and pressure to drive chemical reactions and produce useful products. This is the “brute force” approach. Industrial biotechnology, which utilizes biocatalytic processes, sits at the other end of the spectrum. These platforms use biological pathways in microbial cells — bacterial, fungal, viral, mammalian, floral, and algal — to turn chemical feedstocks into useful chemicals. This is the finesse approach.

A general lack of understanding of how cells interact with genetic tweaking, the shear forces inside a massive bioreactor, and other industrial variables is the biggest problem facing biocatalytic technology. That makes using the methane and ethane found in natural gas as chemical feedstocks a pretty sexy idea. Nat-gas is cheap and the processes involved — or those very similar to it — have been commercially viable since World War 2.

The shorter list of unknowns for thermocatalytic technologies makes returns more certain, which is an important factor to consider when writing eight-figure checks. It also doesn’t help that the massive amounts of natural gas beneath our feet are currently much easier to access than the cellulosic sugars in agricultural wastes. Much like us individual investors, big oil is seeking to mitigate risks and maintain a clearer picture on their potential returns.

A zero-sum game?
Valero Energy Corporation (NYSE:VLO)
was the first major refiner to get into the ethanol business and now owns 10 refineries. The company has kept a broad focus with its renewable energy portfolio, although the largest investments are in thermocatalytic companies such as Enerkem Inc (NASDAQ:NRKM) and several ventures producing biodiesel. Valero Energy Corporation (NYSE:VLO)’s small partnership with algae fuels company Algenol shows that while the company acknowledges the potential, it is still hesitant about throwing much weight behind more advanced biotechnology ideas. The rest of the industry isn’t much different.

Page 1 of 2
Loading Comments...